Background: Glaucoma is one of the leading causes of blindness worldwide. Treatment is
still largely targeted at lowering intraocular pressure. Intraocular pressures can be lowered …

Glaucoma is a complex condition of the eye. It is an ophthalmic neurodegenerative condition
and is characterised by raised intraocular pressure. When left untreated, patients may …

Given that glaucoma is a disease of the central nervous system, there must be greater
emphasis and focus on developing intraocular pressure–independent therapies. In addition …

Introduction Glaucoma is a progressive optic neuropathy and the leading cause of
irreversible vision loss. By 2040, the number of individuals with glaucoma is expected to …

Glaucoma is the most common cause of legal blindness worldwide. This progressive optic
neuropathy is characterized by the degeneration of retinal ganglion cells and consequent …

Lowering intraocular pressure (IOP) is the only proven therapeutic intervention for
glaucomatous optic neuropathy. Despite advances in laser and microsurgical techniques …

The use of generic medicines has grown considerably in recent years providing
considerable cost savings. In England, generic items represented 11.7% of prescriptions for …

Drug Administration Center for Drug Evaluation and Research (FDA CDER) held the
NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium to discuss the …

There are numerous recommendations on how to best use all of the available therapies for
treating glaucoma patients. Such a proliferation of therapies indicates that no one pathway is …

Glaucoma is second to cataract as a leading cause of global blindness and is the leading
cause of irreversible visual loss. By the year 2020, almost 80 million people are estimated to …